Bicycle Therapeutics Stock Falls After Interim Data Of Toxin Conjugates In Ovarian Cancer Trial

Bicycle Therapeutics plc BCYC has reported interim Phase I trial results for BT5528 and preliminary findings from the ongoing dose-escalation portion of the BT8009 trial.
Two BT5528 monotherapy urothelial patients were dosed. Both were observed to have tumor reductions constituting a partial response.
The administered doses in these patients ranged from 6.5mg/m2 to 10 mg/m2 every other week.
Eight BT5528 monotherapy ovarian cancer patients were dosed.
Anti-tumor activity was observed in 4 of 5 patients, including one partial response.
The range of administered doses in these patients was 6.5- 8.5mg/m2 every other week. Bicycle has observed no signs of coagulopathy to date.
Some mild and transient neutropenia was observed at 8.5mg/m2 every week, although this did not constitute dose-limiting toxicity.
Bicycle plans to initiate expansion cohorts for BT5528 with 56 patients in 2022.
The Company also presented preliminary data from the Phase 1 portion of its Phase 1/2 trial of BT8009.
Four patients dosed at 2.5mg/m2 were observed to have tumor reductions, including partial responses, with tumor reductions between 37% to 89%.
Seven response evaluable patients were dosed at 5.0mg/m2 weekly.
Five were observed to have at least stable disease, with a disease control rate of 71%, and three patients were observed to have tumor reductions between 44% to 89%.
Related: Bicycle, Ionis To Develop Targeted Oligonucleotide Therapeutics.
Price Action: BCYC shares are down 12% at $36.69 during the market session on the last check Thursday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga